Abstract

Acute coronary artery disease represents the leading cause of death worldwide. Some studies have shown that coagulation disorders can play a protective role against ischemic heart disease, presumably due to hypocoagulable state and decrease thrombin formation. However, autopsy reports showed atherosclerotic lesions in some patients with hemophilia. Since the introduction of clotting factors and replacement therapies, the life expectancy of patients with coagulation disorders has increased significantly. As a result, the incidence of cardiovascular diseases became higher making their treatment more challenging. Door to balloon strategy applies in ST-elevation myocardial infarction (STEMI), and percutaneous coronary intervention should not be delayed. While in non-STEMI (NSTEMI) and unstable angina, a hematology consult is essential. Prophylactic coagulation factor replacement is crucial in these patients in order to avoid bleeding complications, but on the other hand, these factors were also associated with thrombotic complications. Historically, bare-metal stents were preferred over drug-eluting stents in view of the shorter duration of dual antiplatelets therapy (DAPT). Currently, some trials have demonstrated the safety of new-generation drug-eluting stents in patients with elevated bleeding risk, where DAPT use is limited to four weeks. The radial artery is the preferred access and was found to have less bleeding complications when compared to the femoral access. Anticoagulation with heparin is the safest in view of antidote availability and shorter half-life. Bivalirudin has also been used in some case reports, while GP2b3a inhibitors are usually avoided except in a high thrombus burden. Close peri procedural follow-up is important with patient education about symptoms of bleed. Carefully and individually tailored antithrombotic and factor replacement therapy is required to overcome these clinically challenging situations. Early screening for cardiovascular risk factors and considering early intervention and management might help to improve the general health status of this population and reduce morbidity.

Highlights

  • We aimed to review the literature available for periprocedural and long-term strategies to both minimize the bleeding risk and ensure sufficient anticoagulation and anti-aggregation in patients with coagulation disorders undergoing coronary angiography with percutaneous coronary intervention (PCI)

  • Sparse data are available for the management of acute coronary syndrome among patients with coagulation disorders

  • There are no specific evidence-based guidelines that address the management of CVD risk factors in coagulopathic patients

Read more

Summary

Introduction

We aimed to review the literature available for periprocedural and long-term strategies to both minimize the bleeding risk and ensure sufficient anticoagulation and anti-aggregation in patients with coagulation disorders undergoing coronary angiography with percutaneous coronary intervention (PCI). It is preferred over low molecular weight heparin because of its shorter halflife, lower bleeding risk, and antidote availability It should not be given before complete clotting factor correction is achieved. No major bleeding events were encountered in all these patients This can be secondary to an increase in VWF levels with ACS, as a result of catecholamine surge, which may play a role in better tolerance of antiplatelet and antithrombotic medications [28]. Some studies have shown a protective role of FXI deficiency in ischemic stroke but not in myocardial infarction [32] This indicates that elevated baseline PTT is not protective against coronary disease and the use of anticoagulation is necessary with stent insertion and it should be given under close monitoring of activated clotting time. And individually tailored antithrombotic and factor replacement therapy is required to overcome these clinically challenging situations

Limitations
Conclusions
Findings
Disclosures
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call